×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TCON – tracon pharms inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TCON
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
03:09 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/13
03:02 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/5
02:15 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/28
02:03 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/20
02:08 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/12
02:05 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/4
02:12 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/4
02:12 am
tcon
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/7
04:06 pm
tcon
Form 15-12G Tracon Pharmaceuticals,
High
Report
Form 15-12G Tracon Pharmaceuticals,
11/4
06:03 am
tcon
Form EFFECT Tracon Pharmaceuticals,
High
Report
Form EFFECT Tracon Pharmaceuticals,
11/4
06:03 am
tcon
Form EFFECT Tracon Pharmaceuticals,
High
Report
Form EFFECT Tracon Pharmaceuticals,
11/4
06:02 am
tcon
Form EFFECT Tracon Pharmaceuticals,
High
Report
Form EFFECT Tracon Pharmaceuticals,
11/4
06:02 am
tcon
Form EFFECT Tracon Pharmaceuticals,
High
Report
Form EFFECT Tracon Pharmaceuticals,
11/4
06:02 am
tcon
Form EFFECT Tracon Pharmaceuticals,
High
Report
Form EFFECT Tracon Pharmaceuticals,
11/4
06:02 am
tcon
Form EFFECT Tracon Pharmaceuticals,
High
Report
Form EFFECT Tracon Pharmaceuticals,
11/4
06:02 am
tcon
Form EFFECT Tracon Pharmaceuticals,
High
Report
Form EFFECT Tracon Pharmaceuticals,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/10
TRACON Pharmaceuticals Inc (NASDAQ: TCON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, down previously from $13.00.
40.2%
4/14 TRACON Pharmaceuticals Announces Appointment of Biotechnology Industry Veteran Shahe Garabedian as Senior Vice President of Quality Assurance and Granting of Inducement Award 21.1%
2/28 TRACON Pharmaceuticals Inc (NASDAQ: TCON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock, down previously from $18.00. 13.0%
4/14 Form PRE 14A Tracon Pharmaceuticals, For: Jun 10 12.4%
3/16 TRACON Announces Submission of Request for Type B Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma 12.0%
8/12 Form 4 Tracon Pharmaceuticals, For: Aug 09 Filed by: THEUER CHARLES 8.6%
2/7 TRACON Pharmaceuticals Announces Change to Nasdaq Capital Market 6.5%
10/17 Form 8-K Tracon Pharmaceuticals, For: Oct 16 4.5%
4/6 TRACON Announces May 8 Date for Type B Teleconference Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma 4.4%
11/25 Form EFFECT Tracon Pharmaceuticals, 4.3%
4/14 TRACON Pharmaceuticals Announces Appointment of Biotechnology Industry Veteran Shahe Garabedian as Senior Vice President of Quality Assurance and Granting of Inducement Award 21.1%
2/28 TRACON Pharmaceuticals Inc (NASDAQ: TCON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock, down previously from $18.00. 13.0%
4/14 Form PRE 14A Tracon Pharmaceuticals, For: Jun 10 12.4%
3/16 TRACON Announces Submission of Request for Type B Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma 12.0%
8/12 Form 4 Tracon Pharmaceuticals, For: Aug 09 Filed by: THEUER CHARLES 8.6%
2/7 TRACON Pharmaceuticals Announces Change to Nasdaq Capital Market 6.5%
10/17 Form 8-K Tracon Pharmaceuticals, For: Oct 16 4.5%
4/6 TRACON Announces May 8 Date for Type B Teleconference Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma 4.4%
11/25 Form EFFECT Tracon Pharmaceuticals, 4.3%
TOP News Decliners
3/9
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
-19.1%
3/10 Form 4 Tracon Pharmaceuticals, For: Mar 10 Filed by: THEUER CHARLES -17.5%
4/24 TRACON Pharmaceuticals Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial -16.6%
10/21 Form 8-K Tracon Pharmaceuticals, For: Oct 18 -14.4%
2/28 Form 10-K Tracon Pharmaceuticals, For: Dec 31 -14.4%
1/13 Form 424B5 Tracon Pharmaceuticals, -14.3%
7/2 TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer -11.1%
8/1 I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors -10.0%
3/13 Form 4 Tracon Pharmaceuticals, For: Mar 13 Filed by: THEUER CHARLES -9.7%
8/29 TRACON Pharmaceuticals to Present at the 2019 Wells Fargo Securities Healthcare Conference -9.5%
3/10 Form 4 Tracon Pharmaceuticals, For: Mar 10 Filed by: THEUER CHARLES -17.5%
4/24 TRACON Pharmaceuticals Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial -16.6%
10/21 Form 8-K Tracon Pharmaceuticals, For: Oct 18 -14.4%
2/28 Form 10-K Tracon Pharmaceuticals, For: Dec 31 -14.4%
1/13 Form 424B5 Tracon Pharmaceuticals, -14.3%
7/2 TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer -11.1%
8/1 I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors -10.0%
3/13 Form 4 Tracon Pharmaceuticals, For: Mar 13 Filed by: THEUER CHARLES -9.7%
8/29 TRACON Pharmaceuticals to Present at the 2019 Wells Fargo Securities Healthcare Conference -9.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: